Virax Biolabs GroupVRAX
13F holders, Q4 2024 (December 31)7holders +2
5new positions
4sold out
$2.24avg. 13F price*
At the end of Q4 2024, 7 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, up 2 from Q3 2024. 5 opened new positions and 4 sold out. The largest holders were UBS Group AG ($85K), XTX Topco Ltd ($27K) and Royal Bank of Canada ($23K).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $50K |
| Exits | 4 | $384K |
All 13F filers, Q3 2024 → Q4 2024: 39,777 shares bought and 197,840 shares sold, net −158,063 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Add +84.7% | 37,915 | $85K |
| XTX Topco Ltd | 0.00% | New | 11,863 | $27K |
| Royal Bank of Canada | 0.00% | New | 10,400 | $23K |
| R Squared Ltd | 0.01% | — | 2,700 | $6K |
| Morgan Stanley | 0.00% | New | 100 | $225 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 20 | $45 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 9 | $20 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.